| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
| US6294540 | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
May, 2018
(5 years ago) | |
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6417191 | VIIV HLTHCARE | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Mar, 2016
(8 years ago) | |
|
US6417191 (Pediatric) | VIIV HLTHCARE | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Sep, 2016
(7 years ago) | |
|
US5905082 (Pediatric) | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
|
US6294540 (Pediatric) | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
Nov, 2018
(5 years ago) | |
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) | |
Triumeq is owned by Viiv Hlthcare.
Triumeq contains Abacavir Sulfate; Dolutegravir Sodium; Lamivudine.
Triumeq has a total of 10 drug patents out of which 6 drug patents have expired.
Expired drug patents of Triumeq are:
- US6417191
- US6417191*PED
- US5905082*PED
- US6294540*PED
- US5905082
- US6294540
Triumeq was authorised for market use on 22 August, 2014.
Triumeq is available in tablet;oral dosage forms.
Triumeq can be used as treatment of human immunodeficiency virus (hiv) infection..
Drug patent challenges can be filed against Triumeq from 15 December, 2025.
The generics of Triumeq are possible to be released after 08 June, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-294) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Dosing Schedule(D-147) | Mar 23, 2018 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
NCE-1 date: 15 December, 2025
Market Authorisation Date: 22 August, 2014
Treatment: Treatment of human immunodeficiency virus (hiv) infection.
Dosage: TABLET;ORAL
TRIUMEQ family patents
